Deerfield Management Company LP Series C

-

Assets, Funds, Holdings

Home | Sign Up | Log In
Message
Happy Holidays!! thanks for using AUM13F!!
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Deerfield Management Company LP Series C
CRD #157876
SEC #801-73284
CIK #0001009258
AUM $16.1 B (2025-07-23)
Employees 183 (49% Investors, 0% Brokers)
Phone212-551-1600
Address345 Park Avenue South
New York, NY 10010
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
2016128402011201620212026
Sector Form 13F Holdings Value ($B)
Nuvalent Inc 1.4
Oscar Health Inc 0.2
Upjohn Inc 0.2
Merus NV 0.2
Centene Corp 0.2
Silverback Therapeutics Inc 0.2
Indivior PLC 0.2
United Therapeutics Corp 0.2
Neurocrine Biosciences Inc 0.1
Revolution Medicines Inc 0.1
View All
Holdings by Sector ($B)
7.56.04.53.01.50.02012201620212026
Type Form D Funds Date Sold ($M) AUM ($M)
HF Deerfield Healthcare Innovations Fund III-A LP [2024-02-20] 469.6 62.2
HF Deerfield Healthcare Innovations Fund III LP [2024-02-20] 469.6 402.8
HF Deerfield Private Design Fund V LP [2020-11-24] 0.0 1,464.2
HF Deerfield Healthcare Innovations Fund II LP [2019-08-29] 0.0 837.8
HF Deerfield Private Design Fund IV LP [2017-02-28] 2,391.8 3,861.0
HF Deerfield Healthcare Innovations Fund LP [2015-10-28] 550.0 1,564.5
HF Deerfield Private Design Fund III LP [2014-08-12] 0.0 1,656.5
HF Deerfield International Master Fund LP [2013-03-28] 2,009.8 1,284.9
PE Deerfield PDI Financing II LP 2013-03-28 41.8
HF Deerfield Private Design International II LP [2013-03-28] 270.6 86.1
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 12 16.1
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 12 16.1
By Discretionary
Discretionary 12 16.1
Non-Discretionary 0 0.0
Total 12 16.1
By Non-United States Persons
Non-United States Persons 0.1
United States Persons 15.9
Total 12 16.1
Form D Directors # Filings # Firms 2011 - 2025
Peter Young 116
Graham Cook 79
Nicholas Lane 13
James Flynn 20
Deerfield Mgmt HIF III LP 2
JE Flynn Capital HIF III LLC 2
Deerfield Mgmt V LP 1
JE Flynn Capital HIF II LLC 1
Deerfield Mgmt HIF II LP 1
Deerfield Mgmt HIF LP 1
View All
EDGAR Form CIK 2011 - 2025
13F-HR [0001009258]
3 [0001009258]
4 [0001009258]
SC 13D [0001009258]
Form 13D/13G Filer Form 13D/13G Subject Filed
Deerfield Management Company LP Series C DA32 Life Science Tech Acquisition Corp [2021-08-10]
Deerfield Management Company LP Series C Deerfield Healthcare Technology Acquisitions Corp [2020-07-30]
Form 3/4/5 Subject 2011 - 2025
Deerfield Mgmt L.P.
Flynn James E
Deerfield Healthcare Innovations Fund, L.P.
Deerfield Private Design Fund IV, L.P.
Deerfield Mgmt III, L.P.
Deerfield Mgmt HIF, L.P.
Deerfield Management Company LP
Deerfield Mgmt IV, L.P.
Deerfield Partners LP
Larimar Therapeutics, Inc.
Deerfield Private Design Fund III, L.P.
ARS Pharmaceuticals, Inc.
Nuvalent, Inc.
BiomX Inc.
Deerfield Mgmt V, L.P.
Deerfield Private Design Fund V, L.P.
Deerfield Healthcare Innovations Fund II, L.P.
Acutus Medical, Inc.
Bicara Therapeutics Inc.
Deerfield Mgmt HIF II, L.P.
AdaptHealth Corp.
Fractyl Health Inc
CareMax, Inc.
DA32 Life Science Tech Acquisition Corp.
Oncorus, Inc.
Frazier Lifesciences Acquisition Corp
Mirum Pharmaceuticals, Inc.
PepGen Inc.
Oncology Institute, Inc.
Xilio Therapeutics, Inc.
Deerfield Special Situations Fund, L.P.
Singular Genomics Systems, Inc.
Werewolf Therapeutics, Inc.
Edgewise Therapeutics, Inc.
Terns Pharmaceuticals, Inc.
Peak Bio, Inc.
Lumos Pharma Inc
CalciMedica, Inc.
Annexon, Inc.
Nkarta, Inc.
Generation Bio Co.
Revolution Medicines, Inc.
Schrodinger, Inc.
Black Diamond Therapeutics, Inc.
Q32 Bio Inc.
Cabaletta Bio, Inc.
Korro Bio, Inc.
Aclaris Therapeutics, Inc.
Shockwave Medical, Inc.
Xeris Pharmaceuticals Inc
Arvinas Inc
Aerie Pharmaceuticals Inc
Constellation Pharmaceuticals Inc
Deerfield Private Design Fund II, L.P.
Deerfield Private Design International II, L.P.
Avadel Pharmaceuticals PLC
Breaking Stick Holdings, LLC
Protara Therapeutics, Inc.
Kiniksa Pharmaceuticals International, plc
Mallinckrodt plc
GYRE Therapeutics Inc
Deerfield International Master Fund, L.P.
Rhythm Pharmaceuticals Inc
Societal CDMO, Inc.
eHealth, Inc.
CAS Medical Systems Inc
Invuity, Inc.
Vanda Pharmaceuticals Inc.
Alpine Immune Sciences Inc
Audentes Therapeutics, Inc.
Axogen, Inc.
Syros Pharmaceuticals, Inc.
Xenoport Inc
AveXis, Inc.
Editas Medicine, Inc.
Streamline Health Solutions Inc
Alimera Sciences Inc
CytomX Therapeutics, Inc.
Antares Pharma Inc
REGENXBIO Inc.
Neos Therapeutics, Inc.
Deerfield Private Design Fund L P
Deerfield Private Design International, L.P.
Deerfield Private Design International II, Ltd.
aTYR PHARMA INC
Auspex Pharmaceuticals, Inc.
SteadyMed Ltd.
Invitae Corp
Auxilium Pharmaceuticals Inc
Deerfield Special Situations International Master Fund, L.P.
Dicerna Pharmaceuticals Inc
Loxo Oncology, Inc.
Adverum Biotechnologies, Inc.
TriVascular Technologies, Inc.
Deerfield Special Situations Fund International LTD
Talon Therapeutics, Inc.
Pernix Sleep, Inc.
NxStage Medical, Inc.
Comparable Firms State AUM ($B)
New Holland Capital LLC
NY 17.5
BlackRock Alternatives Management LLC
NY 17.4
OrbiMed Advisors LLC
NY 17.3
Saba Capital Management LP
NY 17.0
First Eagle Alternative Credit LLC
MA 16.8
AIP LLC
NY 16.4
Post Advisory Group LLC
CA 16.0
Abry Partners II LLC
MA 15.5
TFG Asset Management LP
NY 15.2
AEA QP Advisers LLC
NY 14.9
Terms | Privacy | Guide
tony@aum13f.com